J2354
J2354 – Injection, octreotide, non-depot form for subcutaneous or intravenous in · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 44 NDCs crosswalked per 25 MCG $0.596/unit ASP+6%
📋 J2354 summary
J2354 is a HCPCS Level II J-code used to bill octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg, billed per 25 MCG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J2354: Sandostatin, Octreotide Acetate, Octreotide
Code J2354
Billing unit 25 MCG Payment limit $0.596/unit NDC-Crosswalk 44
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ2354
DescriptorInjection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg
Billing unit25 MCG
Payment limit / unit$0.596
Est. ASP / unit$0.562 est.
Mapped NDCs44
Data periodQ3 2026
Last updated2026-08-20
💊 About Octreotide DRUG GUIDE
Octreotide injection (available as Sandostatin, BYNFEZIA Pen, and other octreotide acetate injection products) is used to lower abnormally high growth hormone and IGF-1 levels in acromegaly, and to reduce the severe diarrhea and flushing associated with metastatic carcinoid tumors and the profuse watery diarrhea caused by VIPomas (vasoactive intestinal peptide-secreting tumors).Mycapssa, the oral delayed-release capsule, is approved specifically for long-term maintenance treatment of acromegaly in patients who have already responded to and tolerated treatment with octreotide or lanreotide injections.
It is not indicated for carcinoid tumors or VIPomas.
Clinical overview from our editorial drug guide for Octreotide. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$0.596
Est. ASP / unit
$0.562 est.
Est. after 2% sequester
$0.584
HCPCS dosage
25 MCG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment group—
Action codeN — No maintenance this year
Effective date2004-01-01
Date added2004-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J2354 = 25 mcg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J2354 LEAST EXPENSIVE FIRST
44 NDCs map to J2354. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($0.596/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00641-6175-10 | Octreotide Acetate 100 ug/mL INJECTION, SOLUTION | Hikma | 10 VIAL, SINGLE-DOSE in 1 CARTON (0641-617... | 100 ug/mL | 40 | $23.84 | $2.410 | ● Active | CMS + PDAC |
| 23155-0688-41 | OCTREOTIDE ACETATE 100 ug/mL INJECTION, SOLUTION | Heritage | 10 VIAL, GLASS in 1 CARTON (23155-688-41)... | 100 ug/mL | 40 | $23.84 | $2.410 | ● Active | CMS + PDAC |
| 25021-0464-01 | Octreotide Acetate 100 ug/mL INJECTION, SOLUTION | Sagent | 10 VIAL in 1 CARTON (25021-464-01) / 1 mL... | 100 ug/mL | 40 | $23.84 | $2.410 | Obsolete | CMS + PDAC |
| 63323-0376-01 | Octreotide 100 ug/mL INJECTION, SOLUTION | Fresenius | 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-376-... | 100 ug/mL | 40 | $23.84 | $2.410 | ● Active | CMS + PDAC |
| 63323-0376-04 | Octreotide 100 ug/mL INJECTION, SOLUTION | Fresenius | 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-376-... | 100 ug/mL | 40 | $23.84 | $2.410 | ● Active | CMS ASP |
| 68462-0896-10 | Octreotide Acetate 100 ug/mL INJECTION, SOLUTION | GLENMARK | 10 VIAL in 1 CARTON (68462-896-10) / 1 mL... | 100 ug/mL | 40 | $23.84 | $2.410 | ● Active | CMS + PDAC |
| 00641-6174-10 | Octreotide Acetate 50 ug/mL INJECTION, SOLUTION | Hikma | 10 VIAL, SINGLE-DOSE in 1 CARTON (0641-617... | 50 ug/mL | 20 | $11.92 | $2.642 | ● Active | CMS + PDAC |
| 23155-0687-41 | OCTREOTIDE ACETATE 50 ug/mL INJECTION, SOLUTION | Heritage | 10 VIAL, GLASS in 1 CARTON (23155-687-41)... | 50 ug/mL | 20 | $11.92 | $2.642 | ● Active | CMS + PDAC |
| 25021-0463-01 | Octreotide Acetate 50 ug/mL INJECTION, SOLUTION | Sagent | 10 VIAL in 1 CARTON (25021-463-01) / 1 mL... | 50 ug/mL | 20 | $11.92 | $2.642 | Obsolete | CMS + PDAC |
| 00641-6177-01 | Octreotide Acetate 200 ug/mL INJECTION, SOLUTION | Hikma | 1 VIAL, MULTI-DOSE in 1 CARTON (0641-6177-... | 200 ug/mL | 40 | $23.84 | $5.340 | ● Active | CMS + PDAC |
| 23155-0685-31 | OCTREOTIDE ACETATE 200 ug/mL INJECTION, SOLUTION | Heritage | 5 mL in 1 VIAL, GLASS (23155-685-31) | 200 ug/mL | 40 | $23.84 | $5.340 | ● Active | CMS + PDAC |
| 25021-0466-05 | Octreotide Acetate 200 ug/mL INJECTION, SOLUTION | Sagent | 1 VIAL in 1 CARTON (25021-466-05) / 5 mL... | 200 ug/mL | 40 | $23.84 | $5.340 | Obsolete | CMS + PDAC |
| 63323-0378-05 | Octreotide 200 ug/mL INJECTION, SOLUTION | Fresenius | 1 VIAL, MULTI-DOSE in 1 CARTON (63323-378-... | 200 ug/mL | 40 | $23.84 | $5.340 | ● Active | CMS + PDAC |
| 00078-0180-01 | Sandostatin octreotide acetate 50 ug/mL INJECTION, SOLUTION | Novartis | 10 AMPULE in 1 PACKAGE (0078-0180-01) / 1... | 50 ug/mL | 20 | $11.92 | — | ● Active | CMS + PDAC |
| 00078-0181-01 | Sandostatin octreotide acetate 100 ug/mL INJECTION, SOLUTION | Novartis | 10 AMPULE in 1 PACKAGE (0078-0181-01) / 1... | 100 ug/mL | 40 | $23.84 | — | ● Active | CMS + PDAC |
| 00078-0182-01 | Sandostatin octreotide acetate 500 ug/mL INJECTION, SOLUTION | Novartis | 10 AMPULE in 1 PACKAGE (0078-0182-01) / 1... | 500 ug/mL | 200 | $119.20 | — | ● Active | CMS + PDAC |
| 00641-6176-10 | Octreotide Acetate 500 ug/mL INJECTION, SOLUTION | Hikma | 10 VIAL, SINGLE-DOSE in 1 CARTON (0641-617... | 500 ug/mL | 200 | $119.20 | — | ● Active | CMS + PDAC |
| 00641-6178-01 | Octreotide Acetate 1000 ug/mL INJECTION, SOLUTION | Hikma | 1 VIAL, MULTI-DOSE in 1 CARTON (0641-6178-... | 1000 ug/mL | 200 | $119.20 | — | ● Active | CMS + PDAC |
| 23155-0686-31 | OCTREOTIDE ACETATE 1000 ug/mL INJECTION, SOLUTION | Heritage | 5 mL in 1 VIAL, GLASS (23155-686-31) | 1000 ug/mL | 200 | $119.20 | — | ● Active | CMS + PDAC |
| 23155-0689-41 | OCTREOTIDE ACETATE 500 ug/mL INJECTION, SOLUTION | Heritage | 10 VIAL, GLASS in 1 CARTON (23155-689-41)... | 500 ug/mL | 200 | $119.20 | — | ● Active | CMS + PDAC |
| 25021-0451-01 | Octreotide Acetate | Sagent | — | — | 20 | $11.92 | — | — | CMS ASP |
| 25021-0452-01 | Octreotide Acetate | Sagent | — | — | 40 | $23.84 | — | — | CMS ASP |
| 25021-0453-01 | Octreotide Acetate | Sagent | — | — | 200 | $119.20 | — | — | CMS ASP |
| 25021-0454-05 | Octreotide Acetate | Sagent | — | — | 40 | $23.84 | — | — | CMS ASP |
| 25021-0465-01 | Octreotide Acetate 500 ug/mL INJECTION, SOLUTION | Sagent | 10 VIAL in 1 CARTON (25021-465-01) / 1 mL... | 500 ug/mL | 200 | $119.20 | — | Obsolete | CMS + PDAC |
| 25021-0467-05 | Octreotide Acetate 1000 ug/mL INJECTION, SOLUTION | Sagent | 1 VIAL in 1 CARTON (25021-467-05) / 5 mL... | 1000 ug/mL | 200 | $119.20 | — | Obsolete | CMS + PDAC |
| 63323-0377-01 | Octreotide 500 ug/mL INJECTION, SOLUTION | Fresenius | 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-377-... | 500 ug/mL | 200 | $119.20 | — | ● Active | CMS + PDAC |
| 63323-0377-04 | Octreotide 500 ug/mL INJECTION, SOLUTION | Fresenius | 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-377-... | 500 ug/mL | 200 | $119.20 | — | ● Active | CMS ASP |
| 63323-0379-05 | Octreotide 1000 ug/mL INJECTION, SOLUTION | Fresenius | 1 VIAL, MULTI-DOSE in 1 CARTON (63323-379-... | 1000 ug/mL | 200 | $119.20 | — | ● Active | CMS + PDAC |
| 67457-0239-01 | Octreotide Acetate 50 ug/mL INJECTION, SOLUTION | Mylan | 10 SYRINGE in 1 CARTON (67457-239-01) / 1... | 50 ug/mL | 20 | $11.92 | — | ● Active | CMS ASP |
| 67457-0245-01 | Octreotide Acetate 100 ug/mL INJECTION, SOLUTION | Mylan | 10 SYRINGE in 1 CARTON (67457-245-01) / 1... | 100 ug/mL | 40 | $23.84 | — | ● Active | CMS ASP |
| 67457-0246-01 | Octreotide Acetate 500 ug/mL INJECTION, SOLUTION | Mylan | 10 SYRINGE in 1 CARTON (67457-246-01) / 1... | 500 ug/mL | 200 | $119.20 | — | ● Active | CMS ASP |
| 68462-0897-10 | Octreotide Acetate 500 ug/mL INJECTION, SOLUTION | GLENMARK | 10 VIAL in 1 CARTON (68462-897-10) / 1 mL... | 500 ug/mL | 200 | $119.20 | — | ● Active | CMS + PDAC |
| 71288-0566-02 | Octreotide Acetate 50 ug/mL INJECTION, SOLUTION | Meitheal | 10 VIAL, SINGLE-DOSE in 1 CARTON (71288-56... | 50 ug/mL | 20 | $11.92 | — | ● Active | CMS + PDAC |
| 71288-0567-02 | Octreotide Acetate 100 ug/mL INJECTION, SOLUTION | Meitheal | 10 VIAL, SINGLE-DOSE in 1 CARTON (71288-56... | 100 ug/mL | 40 | $23.84 | — | ● Active | CMS + PDAC |
| 71288-0568-02 | Octreotide Acetate 500 ug/mL INJECTION, SOLUTION | Meitheal | 10 VIAL, SINGLE-DOSE in 1 CARTON (71288-56... | 500 ug/mL | 200 | $119.20 | — | ● Active | CMS + PDAC |
| 00781-9167-95 | OCTREOTIDE ACETATE NOVAPLUS (M.D.V.) 100 MCG/ML | Unknown | — | — | 4 | $2.38 | — | — | PDAC |
| 00781-9166-95 | OCTREOTIDE ACETATE NOVAPLUS (M.D.V.) 50 MCG/ML | Unknown | — | — | 2 | $1.19 | — | — | PDAC |
| 00781-9168-95 | OCTREOTIDE ACETATE NOVAPLUS (M.D.V.) 500 MCG/ML | Unknown | — | — | 20 | $11.92 | — | — | PDAC |
| 00703-3333-01 | OCTREOTIDE ACETATE 200 MCG/ML | Unknown | — | — | 8 | $4.77 | — | — | PDAC |
| 00703-3343-01 | OCTREOTIDE ACETATE 1000 MCG/ML | Unknown | — | — | 40 | $23.84 | — | — | PDAC |
| 00703-3301-04 | OCTREOTIDE ACETATE (1MLX25 VIALS) 50 MCG/ML | Unknown | — | — | 2 | $1.19 | — | — | PDAC |
| 00703-3311-04 | OCTREOTIDE ACETATE (1MLX25 VIALS) 100 MCG/ML | Unknown | — | — | 4 | $2.38 | — | — | PDAC |
| 00703-3321-04 | OCTREOTIDE ACETATE (1MLX25 VIALS) 500 MCG/ML | Unknown | — | — | 20 | $11.92 | — | — | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2025 (Q1-Q4)
Total Part B spend
$25.1K
Claims
17
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$1,478.88
Where J2354 ranks among Part B drugs · 2025 (Q1-Q4) · neighbors ±5
Total spending — #762 of 918
#757
BUPIVACAINE HCL* J0665
$28.1K
#758
HYLENEX J3473
$28.1K
#759
PREMARIN J1410
$27.2K
#760
CALCIUM GLUCONATE-NA... J0612
$26K
#761
DELESTROGEN* J1380
$25.3K
#762
OCTREOTIDE ACETATE* J2354
$25.1K
#763
ZEVTERA J0681
$24.2K
#764
HALDOL DECANOATE 100... J1631
$23.7K
#765
DEMEROL* J2175
$23.7K
#766
MATRISTEM MICROMATRI... Q4118
$23.6K
#767
LEVOTHYROXINE SODIUM... J0650
$22.9K
Total claims — #899 of 918
#894
ACESSO AC, PER SQ CM... Q4312
20
#895
INJ, EPINEPHRINE (BE... J0173
18
#896
DECITABINE J0893
18
#897
VANCOMYCIN HCL(J3372... J3372
18
#898
CEFEPIME-DEXTROSE J0703
17
#899
OCTREOTIDE ACETATE* J2354
17
#900
VANCOMYCIN HCL(J3371... J3371
17
#901
DAUNORUBICIN HCL J9150
17
#902
SURGRAFT FT PER SQ C... Q4268
17
#903
DIGIFAB J1162
16
#904
ARISTADA INITIO J1943
16
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (1)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2025 (Q1-Q4) | $25.1K | — | 17 | — | $1,478.88 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$15.9K
Medicare paid
$12.5K
Submitted services
58,999
Denial rate
63.3%
Allowed / service
$0.74
Submitted charges
$1.12M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
📊 What bills under J2354
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
44 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2025
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J2354 billing FAQ
What is HCPCS code J2354?
J2354 is a HCPCS Level II J-code used to bill Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J2354?
One unit of J2354 represents 25 MCG. Report the number of units equal to the dose administered divided by 25 MCG.
How many units of J2354 should I bill?
Divide the dose administered by the code's unit size (25 MCG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J2354?
The Medicare Part B payment limit is $0.596 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $0.584 per unit. Payment limits are revised quarterly.
Which NDCs bill under J2354?
44 NDCs currently map to J2354 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J2354 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.